433 related articles for article (PubMed ID: 34239267)
1. Hepatitis delta virus: From infection to new therapeutic strategies.
Niro GA; Ferro A; Cicerchia F; Brascugli I; Durazzo M
World J Gastroenterol; 2021 Jun; 27(24):3530-3542. PubMed ID: 34239267
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis D: A Review.
Negro F; Lok AS
JAMA; 2023 Dec; 330(24):2376-2387. PubMed ID: 37943548
[TBL] [Abstract][Full Text] [Related]
3. Future treatments for hepatitis delta virus infection.
Asselah T; Loureiro D; Tout I; Castelnau C; Boyer N; Marcellin P; Mansouri A
Liver Int; 2020 Feb; 40 Suppl 1():54-60. PubMed ID: 32077603
[TBL] [Abstract][Full Text] [Related]
4. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.
Lütgehetmann M; Mancke LV; Volz T; Helbig M; Allweiss L; Bornscheuer T; Pollok JM; Lohse AW; Petersen J; Urban S; Dandri M
Hepatology; 2012 Mar; 55(3):685-94. PubMed ID: 22031488
[TBL] [Abstract][Full Text] [Related]
5. An update on HDV: virology, pathogenesis and treatment.
Alvarado-Mora MV; Locarnini S; Rizzetto M; Pinho JR
Antivir Ther; 2013; 18(3 Pt B):541-8. PubMed ID: 23792471
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic.
Sagnelli C; Pisaturo M; Curatolo C; Codella AV; Coppola N; Sagnelli E
World J Gastroenterol; 2021 Nov; 27(42):7271-7284. PubMed ID: 34876788
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis Delta Virus Alters the Autophagy Process To Promote Its Genome Replication.
Khabir M; Aliche AZ; Sureau C; Blanchet M; Labonté P
J Virol; 2020 Jan; 94(4):. PubMed ID: 31748400
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study.
Manesis EK; Vourli G; Dalekos G; Vasiliadis T; Manolaki N; Hounta A; Koutsounas S; Vafiadis I; Nikolopoulou G; Giannoulis G; Germanidis G; Papatheodoridis G; Touloumi G
J Hepatol; 2013 Nov; 59(5):949-56. PubMed ID: 23850875
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis delta: Epidemiology to recent advances in therapeutic agents.
Abdul Majeed N; Zehnder B; Koh C; Heller T; Urban S
Hepatology; 2023 Oct; 78(4):1306-1321. PubMed ID: 36738087
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis Delta Infection: A Clinical Review.
Pearlman B
Semin Liver Dis; 2023 Aug; 43(3):293-304. PubMed ID: 37473778
[TBL] [Abstract][Full Text] [Related]
12. Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection.
Giersch K; Helbig M; Volz T; Allweiss L; Mancke LV; Lohse AW; Polywka S; Pollok JM; Petersen J; Taylor J; Dandri M; Lütgehetmann M
J Hepatol; 2014 Mar; 60(3):538-44. PubMed ID: 24280293
[TBL] [Abstract][Full Text] [Related]
13. High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort.
Bockmann JH; Grube M; Hamed V; von Felden J; Landahl J; Wehmeyer M; Giersch K; Hall MT; Murray JM; Dandri M; Lüth S; Lohse AW; Lütgehetmann M; Schulze Zur Wiesch J
BMC Gastroenterol; 2020 Jan; 20(1):24. PubMed ID: 32000689
[TBL] [Abstract][Full Text] [Related]
14. Management of hepatitis delta: Need for novel therapeutic options.
Abbas Z; Abbas M
World J Gastroenterol; 2015 Aug; 21(32):9461-5. PubMed ID: 26327754
[TBL] [Abstract][Full Text] [Related]
15. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?
Sheldon J; Ramos B; Toro C; Ríos P; Martínez-Alarcón J; Bottecchia M; Romero M; Garcia-Samaniego J; Soriano V
Antivir Ther; 2008; 13(1):97-102. PubMed ID: 18389903
[TBL] [Abstract][Full Text] [Related]
16. Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.
Winer BY; Shirvani-Dastgerdi E; Bram Y; Sellau J; Low BE; Johnson H; Huang T; Hrebikova G; Heller B; Sharon Y; Giersch K; Gerges S; Seneca K; Pais MA; Frankel AS; Chiriboga L; Cullen J; Nahass RG; Lutgehetmann M; Toettcher JE; Wiles MV; Schwartz RE; Ploss A
Sci Transl Med; 2018 Jun; 10(447):. PubMed ID: 29950446
[TBL] [Abstract][Full Text] [Related]
17. Characterization of hepatitis B and delta coinfection in Israel.
Shirazi R; Ram D; Rakovsky A; Bucris E; Gozlan Y; Lustig Y; Shaked-Mishan P; Picard O; Shemer-Avni Y; Ben-Zvi H; Halutz O; Lurie Y; Veizman E; Carlebach M; Braun M; Naftaly MC; Shlomai A; Safadi R; Mendelson E; Sklan EH; Ben-Ari Z; Mor O
BMC Infect Dis; 2018 Feb; 18(1):97. PubMed ID: 29486716
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis D virus dual-infection among Chinese hepatitis B patient related to hepatitis B surface antigen, hepatitis B virus DNA and age.
Zi J; Li YH; Wang XM; Xu HQ; Liu WH; Cui JY; Niu JQ; Chi XM
World J Gastroenterol; 2023 Oct; 29(38):5395-5405. PubMed ID: 37900584
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and clinical significance of hepatitis D virus co-infection in patients with chronic hepatitis B in Korea.
Kim HS; Kim SJ; Park HW; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
J Med Virol; 2011 Jul; 83(7):1172-7. PubMed ID: 21541950
[TBL] [Abstract][Full Text] [Related]
20. Emerging anti-HDV drugs and HBV cure strategies with anti-HDV activity.
Roca Suarez AA; Batbold E; Bartosch B; Dashdorj N; Testoni B; Zoulim F
Liver Int; 2023 Aug; 43 Suppl 1():87-95. PubMed ID: 37017060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
